Salute e Benessere
Adrenocortical Carcinoma Market to Exhibit Growth at a CAGR of 11.1% by 2034 | DelveInsight
Discover which therapies are expected to grab the major adrenocortical carcinoma market share @
Adrenocortical carcinoma is a rare but aggressive cancer originating in the adrenal cortex. The cause of adrenocortical carcinoma is largely unknown, though genetic mutations and hereditary conditions are believed to play a role. Risk factors include age, gender differences, and specific genetic tendencies. Symptoms of adrenocortical carcinoma include abdominal pain, unexplained weight loss, hormonal imbalances, and detectable abdominal masses. Due to its rarity and vague symptoms, early detection is often difficult. Adrenocortical carcinoma progresses through four stages. Stages I and II are characterized by localized disease, Stage III involves lymph node involvement, and Stage IV indicates advanced disease with metastasis to distant organs.
Diagnosing adrenocortical carcinoma involves a thorough process beginning with a review of medical history and a physical examination to identify abnormalities in the adrenal gland. Imaging tests such as CT, MRI, and PET scans are used to visualize tumors and assess their spread. Blood and urine tests are conducted to measure hormone levels and metabolic markers. Although biopsies provide a definitive diagnosis, they come with risks and are not always performed. Genetic testing might be recommended, especially if there is a family history of the disease. Staging scans help guide treatment options, which typically include surgery, chemotherapy, radiation, or targeted therapy, all coordinated by multidisciplinary healthcare teams.
DelveInsight's analyst forecasts that around of all adrenocortical carcinoma cases in the 7MM originate from the United States . Based on our calculations, the EU4 and the UK together saw incident cases of adrenocortical carcinoma (ACC) in 2023.
The adrenocortical carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
First-line therapies for adrenocortical carcinoma involve a personalized approach tailored to patient-specific prognostic factors. Treatment strategies vary based on these factors, incorporating both local and systemic methods. Patients with good performance status and aggressive disease may undergo combination therapy, such as , which includes etoposide, doxorubicin, cisplatin, and mitotane. In contrast, those with less aggressive disease might receive mitotane monotherapy, sometimes supplemented with locoregional therapies.
Despite the effectiveness of EDP-M as a first-line therapy for adrenocortical carcinoma, patient prognosis remains poor. Second-line treatments, such as , show limited response rates (around 10%). Although G+C is considered modestly effective, it lacks significant predictive molecular markers but generally has tolerable side effects.
used as a third-line chemotherapy for advanced adrenocortical carcinoma, demonstrates anti-tumor activity in vitro. While some clinical studies show disease control in certain patients, its overall efficacy is limited. Ongoing research seeks to define temozolomide's optimal role, especially in identifying patient subsets that may respond well to treatment.
Future advances in adrenocortical carcinoma treatment may utilize new chemotherapeutic agents, vascular growth inhibitors, and small-molecule therapies, driven by a better understanding of the molecular pathways involved in tumorigenesis. These emerging strategies hold promise for improving therapeutic efficacy and patient outcomes.
Learn more about the FDA-approved drugs for adrenocortical carcinoma @
The lack of research and development efforts in adrenocortical carcinoma is due to its categorization as an ultra rare disease, indicating a limited pipeline with only a handful of therapies in Phase II, Phase I/II, and preclinical investigations. With only one double combination therapy, " ," showing promise in emerging in the ACC landscape, the field faces considerable challenges. However, this underscores the urgent need for increased investment and focus to propel adrenocortical carcinoma treatment strategies forward.
, an innovative therapeutic vaccine derived from the microbiome and developed by Enterome, is designed to combat solid tumors such as glioblastoma and adrenocortical carcinoma. By utilizing specific peptides that mimic antigens associated with tumors and triggering immune responses, it seeks to instigate a focused attack by memory T cells against tumor cells. Clinical trials, particularly in cases of glioblastoma, have demonstrated robust immune responses, encouraging efficacy, and a favorable safety profile, especially when combined with checkpoint inhibitors. EO2401 is also exhibiting promise in trials for adrenocortical carcinoma.
is currently assessing EO2401 in a clinical trial for treating adrenal tumors (SPENCER study, EOADR1-19). In March 2021 , Enterome entered into a clinical trial collaboration and supply agreement with to support EO2401, an OncoMimics vaccine in clinical development. Under this agreement, BMS has committed to providing nivolumab at no cost for patients participating in the combined therapy clinical trial .
are two promising pharmaceutical candidates currently progressing through clinical development for adrenocortical carcinoma. CyPep-1, a synthetic peptide targeting tumor membranes with 27-D-amino acids in an alpha-helical structure, is being developed by . It is set to begin Phase II clinical trials in the first half of 2024 as a standalone treatment for adrenocortical carcinoma.
On the other hand, from adrenocortical carcinoma is a novel preclinical compound designed as an oral antagonist targeting the orphan nuclear receptor steroidogenic factor-1 (SF-1 or NR5A1). Notably, OR-449 has received a from the FDA. Consequently, the company plans to submit an IND application to the FDA later this year, marking the initiation of Phase I clinical trials. These innovative therapies, projected to become available in the therapeutic market between 2024 and 2034, are poised to significantly advance the treatment options for adrenocortical carcinoma.
Discover more about adrenocortical carcinoma drugs in development @
The dynamics of the adrenocortical carcinoma market are expected to change in the coming years. The like adrenalectomy, along with the exclusive approval of Mitotane, consolidating its position as the primary therapeutic option for adrenocortical carcinoma, and the to address immunotherapy resistance, presents a significant of adrenocortical carcinoma, enhancing treatment accessibility and inviting key market players to enter.
Furthermore, many potential therapies are being investigated for the treatment of adrenocortical carcinoma, and it is safe to predict that the treatment space will significantly impact the adrenocortical carcinoma market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the adrenocortical carcinoma market in the 7MM.
However several factors may impede the growth of the adrenocortical carcinoma market. The , coupled with surgery as the primary treatment, poses a weakness due to restricted treatment options for adrenocortical carcinoma, exacerbated by the rarity of the disease, hindering large-scale clinical trials and challenging evidence-based treatment guidelines. Furthermore, to existing adrenocortical carcinoma treatment options, like mitotane monotherapy, lead to unfavorable patient outcomes, posing a critical challenge, further compounded by the due to adrenocortical carcinoma's ultra-rare status, which poses a significant threat.
Moreover, adrenocortical carcinoma treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the adrenocortical carcinoma market growth may be offset by , , , and a . In addition, the about the disease may also impact the adrenocortical carcinoma market growth.
To know more about adrenocortical carcinoma treatment guidelines, visit @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key adrenocortical carcinoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted adrenocortical carcinoma epidemiology in the 7MM, i.e., the United States , EU5 ( Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key congenital adrenal hyperplasia companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key congenital adrenal hyperplasia companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/adrenocortical-carcinoma-market-to-exhibit-growth-at-a-cagr-of-11-1-by-2034--delveinsight-302170493.html